Gaston, B., Drazen, J
Although a recent trial has shown to be beneficial when antiviral treatment is introduced early during the disease before hospitalization than later in the course of the disease, there is an urgent need for early therapies to reduce the risk of disease progression, prevent transmission, and be widely distributed to meet the worldwide demand (Gottlieb et al., 2022
Product Overview BPC-157 / TB-500 combines two extensively studied peptide compounds within a single research preparation designed for controlled laboratory investigations involving peptide signalling systems, molecular communication pathways and peptide interaction models
Topical and Injectable GHK-Cu Routes Compared Topical GHK-Cu has published cosmetic, wound, and trial-context evidence, while injectable GHK-Cu lacks an FDA-approved dosing label and is specifically discussed by FDA in relation to compounded injectable safety concerns [2], [3], [7], [8]
To conclude it doesn't work for you